The global market for Non Alcoholic Fatty Liver Disease Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.

North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.

This report aims to provide a comprehensive presentation of the global market for Non Alcoholic Fatty Liver Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non Alcoholic Fatty Liver Disease Treatment.

The Non Alcoholic Fatty Liver Disease Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non Alcoholic Fatty Liver Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non Alcoholic Fatty Liver Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non Alcoholic Fatty Liver Disease Treatment Market Report

Report Metric	Details
Report Name	Non Alcoholic Fatty Liver Disease Treatment Market
Segment by Type	Antioxidants Thiazolidinedione Biguanides Lipid lowering Agents FXR Receptor Agonist Others
Segment by Application	Hospital Pharmacy Retail Pharmacy Drug Stores Online Pharmacy Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Roche, Daewoong, Cardax, Merck, Novartis, Gilead Sciences, AstraZeneca, Limerick BioPharma, GW Pharmaceuticals, Allergan, Takeda Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non Alcoholic Fatty Liver Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Non Alcoholic Fatty Liver Disease Treatment Market report?

Ans: The main players in the Non Alcoholic Fatty Liver Disease Treatment Market are Pfizer, Roche, Daewoong, Cardax, Merck, Novartis, Gilead Sciences, AstraZeneca, Limerick BioPharma, GW Pharmaceuticals, Allergan, Takeda Pharmaceutical

What are the Application segmentation covered in the Non Alcoholic Fatty Liver Disease Treatment Market report?

Ans: The Applications covered in the Non Alcoholic Fatty Liver Disease Treatment Market report are Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy, Others

What are the Type segmentation covered in the Non Alcoholic Fatty Liver Disease Treatment Market report?

Ans: The Types covered in the Non Alcoholic Fatty Liver Disease Treatment Market report are Antioxidants, Thiazolidinedione, Biguanides, Lipid lowering Agents, FXR Receptor Agonist, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antioxidants

1.2.3 Thiazolidinedione

1.2.4 Biguanides

1.2.5 Lipid lowering Agents

1.2.6 FXR Receptor Agonist

1.2.7 Others

1.3 Market by Application

1.3.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Drug Stores

1.3.5 Online Pharmacy

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Perspective (2020-2031)

2.2 Global Non Alcoholic Fatty Liver Disease Treatment Growth Trends by Region

2.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Region (2020-2025)

2.2.3 Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Region (2026-2031)

2.3 Non Alcoholic Fatty Liver Disease Treatment Market Dynamics

2.3.1 Non Alcoholic Fatty Liver Disease Treatment Industry Trends

2.3.2 Non Alcoholic Fatty Liver Disease Treatment Market Drivers

2.3.3 Non Alcoholic Fatty Liver Disease Treatment Market Challenges

2.3.4 Non Alcoholic Fatty Liver Disease Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue

3.1.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue (2020-2025)

3.1.2 Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Non Alcoholic Fatty Liver Disease Treatment Revenue

3.4 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio

3.4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2024

3.5 Global Key Players of Non Alcoholic Fatty Liver Disease Treatment Head office and Area Served

3.6 Global Key Players of Non Alcoholic Fatty Liver Disease Treatment, Product and Application

3.7 Global Key Players of Non Alcoholic Fatty Liver Disease Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Non Alcoholic Fatty Liver Disease Treatment Breakdown Data by Type

4.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Type (2020-2025)

4.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Type (2026-2031)

5 Non Alcoholic Fatty Liver Disease Treatment Breakdown Data by Application

5.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Application (2020-2025)

5.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size (2020-2031)

6.2 North America Non Alcoholic Fatty Liver Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025)

6.4 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size (2020-2031)

7.2 Europe Non Alcoholic Fatty Liver Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025)

7.4 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size (2020-2031)

8.2 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size (2020-2031)

9.2 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025)

9.4 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size (2020-2031)

10.2 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Non Alcoholic Fatty Liver Disease Treatment Introduction

11.1.4 Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche Non Alcoholic Fatty Liver Disease Treatment Introduction

11.2.4 Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.2.5 Roche Recent Development

11.3 Daewoong

11.3.1 Daewoong Company Details

11.3.2 Daewoong Business Overview

11.3.3 Daewoong Non Alcoholic Fatty Liver Disease Treatment Introduction

11.3.4 Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.3.5 Daewoong Recent Development

11.4 Cardax

11.4.1 Cardax Company Details

11.4.2 Cardax Business Overview

11.4.3 Cardax Non Alcoholic Fatty Liver Disease Treatment Introduction

11.4.4 Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.4.5 Cardax Recent Development

11.5 Merck

11.5.1 Merck Company Details

11.5.2 Merck Business Overview

11.5.3 Merck Non Alcoholic Fatty Liver Disease Treatment Introduction

11.5.4 Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.5.5 Merck Recent Development

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Non Alcoholic Fatty Liver Disease Treatment Introduction

11.6.4 Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.6.5 Novartis Recent Development

11.7 Gilead Sciences

11.7.1 Gilead Sciences Company Details

11.7.2 Gilead Sciences Business Overview

11.7.3 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Introduction

11.7.4 Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.7.5 Gilead Sciences Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Introduction

11.8.4 AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Limerick BioPharma

11.9.1 Limerick BioPharma Company Details

11.9.2 Limerick BioPharma Business Overview

11.9.3 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Introduction

11.9.4 Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.9.5 Limerick BioPharma Recent Development

11.10 GW Pharmaceuticals

11.10.1 GW Pharmaceuticals Company Details

11.10.2 GW Pharmaceuticals Business Overview

11.10.3 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Introduction

11.10.4 GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.10.5 GW Pharmaceuticals Recent Development

11.11 Allergan

11.11.1 Allergan Company Details

11.11.2 Allergan Business Overview

11.11.3 Allergan Non Alcoholic Fatty Liver Disease Treatment Introduction

11.11.4 Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.11.5 Allergan Recent Development

11.12 Takeda Pharmaceutical

11.12.1 Takeda Pharmaceutical Company Details

11.12.2 Takeda Pharmaceutical Business Overview

11.12.3 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Introduction

11.12.4 Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

11.12.5 Takeda Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Takeda Pharmaceutical

List of Tables

Table 1. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antioxidants

Table 3. Key Players of Thiazolidinedione

Table 4. Key Players of Biguanides

Table 5. Key Players of Lipid lowering Agents

Table 6. Key Players of FXR Receptor Agonist

Table 7. Key Players of Others

Table 8. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 11. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Region (2020-2025)

Table 12. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 13. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Region (2026-2031)

Table 14. Non Alcoholic Fatty Liver Disease Treatment Market Trends

Table 15. Non Alcoholic Fatty Liver Disease Treatment Market Drivers

Table 16. Non Alcoholic Fatty Liver Disease Treatment Market Challenges

Table 17. Non Alcoholic Fatty Liver Disease Treatment Market Restraints

Table 18. Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Players (2020-2025)

Table 20. Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2024)

Table 21. Ranking of Global Top Non Alcoholic Fatty Liver Disease Treatment Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Non Alcoholic Fatty Liver Disease Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Non Alcoholic Fatty Liver Disease Treatment, Headquarters and Area Served

Table 24. Global Key Players of Non Alcoholic Fatty Liver Disease Treatment, Product and Application

Table 25. Global Key Players of Non Alcoholic Fatty Liver Disease Treatment, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 28. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2020-2025)

Table 29. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 30. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2026-2031)

Table 31. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 32. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application (2020-2025)

Table 33. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 34. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application (2026-2031)

Table 35. North America Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 40. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 41. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 43. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 44. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 49. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 50. Pfizer Company Details

Table 51. Pfizer Business Overview

Table 52. Pfizer Non Alcoholic Fatty Liver Disease Treatment Product

Table 53. Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 54. Pfizer Recent Development

Table 55. Roche Company Details

Table 56. Roche Business Overview

Table 57. Roche Non Alcoholic Fatty Liver Disease Treatment Product

Table 58. Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 59. Roche Recent Development

Table 60. Daewoong Company Details

Table 61. Daewoong Business Overview

Table 62. Daewoong Non Alcoholic Fatty Liver Disease Treatment Product

Table 63. Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 64. Daewoong Recent Development

Table 65. Cardax Company Details

Table 66. Cardax Business Overview

Table 67. Cardax Non Alcoholic Fatty Liver Disease Treatment Product

Table 68. Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 69. Cardax Recent Development

Table 70. Merck Company Details

Table 71. Merck Business Overview

Table 72. Merck Non Alcoholic Fatty Liver Disease Treatment Product

Table 73. Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 74. Merck Recent Development

Table 75. Novartis Company Details

Table 76. Novartis Business Overview

Table 77. Novartis Non Alcoholic Fatty Liver Disease Treatment Product

Table 78. Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 79. Novartis Recent Development

Table 80. Gilead Sciences Company Details

Table 81. Gilead Sciences Business Overview

Table 82. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Product

Table 83. Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 84. Gilead Sciences Recent Development

Table 85. AstraZeneca Company Details

Table 86. AstraZeneca Business Overview

Table 87. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Product

Table 88. AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 89. AstraZeneca Recent Development

Table 90. Limerick BioPharma Company Details

Table 91. Limerick BioPharma Business Overview

Table 92. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Product

Table 93. Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 94. Limerick BioPharma Recent Development

Table 95. GW Pharmaceuticals Company Details

Table 96. GW Pharmaceuticals Business Overview

Table 97. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Product

Table 98. GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 99. GW Pharmaceuticals Recent Development

Table 100. Allergan Company Details

Table 101. Allergan Business Overview

Table 102. Allergan Non Alcoholic Fatty Liver Disease Treatment Product

Table 103. Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 104. Allergan Recent Development

Table 105. Takeda Pharmaceutical Company Details

Table 106. Takeda Pharmaceutical Business Overview

Table 107. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Product

Table 108. Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025) & (US$ Million)

Table 109. Takeda Pharmaceutical Recent Development

Table 110. Research Programs/Design for This Report

Table 111. Key Data Information from Secondary Sources

Table 112. Key Data Information from Primary Sources

Table 113. Authors List of This Report

List of Figures

Figure 1. Non Alcoholic Fatty Liver Disease Treatment Picture

Figure 2. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Type: 2024 VS 2031

Figure 4. Antioxidants Features

Figure 5. Thiazolidinedione Features

Figure 6. Biguanides Features

Figure 7. Lipid lowering Agents Features

Figure 8. FXR Receptor Agonist Features

Figure 9. Others Features

Figure 10. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 11. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Application: 2024 VS 2031

Figure 12. Hospital Pharmacy Case Studies

Figure 13. Retail Pharmacy Case Studies

Figure 14. Drug Stores Case Studies

Figure 15. Online Pharmacy Case Studies

Figure 16. Others Case Studies

Figure 17. Non Alcoholic Fatty Liver Disease Treatment Report Years Considered

Figure 18. Global Non Alcoholic Fatty Liver Disease Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 19. Global Non Alcoholic Fatty Liver Disease Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 20. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Region: 2024 VS 2031

Figure 21. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Players in 2024

Figure 22. Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2024)

Figure 23. The Top 10 and 5 Players Market Share by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2024

Figure 24. North America Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. North America Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2020-2031)

Figure 26. United States Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Canada Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2020-2031)

Figure 30. Germany Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. France Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. U.K. Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Italy Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Russia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Nordic Countries Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Share by Region (2020-2031)

Figure 38. China Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Japan Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. South Korea Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. India Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Australia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2020-2031)

Figure 46. Mexico Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Brazil Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2020-2031)

Figure 50. Turkey Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. UAE Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Pfizer Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 54. Roche Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 55. Daewoong Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 56. Cardax Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 57. Merck Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 58. Novartis Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 59. Gilead Sciences Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 60. AstraZeneca Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 61. Limerick BioPharma Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 62. GW Pharmaceuticals Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 63. Allergan Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 64. Takeda Pharmaceutical Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Non Alcoholic Steatohepatitis NASH Therapeutics and Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non Alcoholic Steatohepatitis Treatment Market Research Report 2025

Non Alcoholic Steatohepatitis Therapeutics and Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nonalcoholic Steatohepatitis Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global NASH Non alcoholic Steatohepatitis Biomarkers Market Research Report 2024

Nonalcoholic Steatohepatitis NASH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nonalcoholic Steatohepatitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Fatty Liver Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Alcoholic Hepatitis Treatment Market Insights Forecast to 2030

Global Compensated Cirrhosis Type C Market Research Report 2024

Global Non Alcoholic Steatohepatitis NASH Treatment Market Insights Forecast to 2030

Non Alcoholic Steatohepatitis Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Liver Cirrhosis Market Research Report 2024

Global Non alcoholic Steatohepatitis NASH Biomarkers Market Research Report 2024

Alcoholic Liver Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non Invasive Liver Monitor Market Research Report 2024

Global Cardiac Cirrhosis Treatment Market Research Report 2024

Liver Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Liver Cirrhosis Treatment Market Research Report 2025

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19Z7671

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10V14317

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10O5919

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4I19963

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions